CT测量的肌肉与脂肪含量与非转移性乳腺癌生存的关联
该观察性研究纳入3241例II-III期乳腺癌女性,利用诊断时临床CT评估肌肉减少症、低肌肉放射密度和总脂肪组织与全因死亡的关系。中位随访6.0年,肌肉减少症患者全因死亡风险更高(HR 1.41;95%CI 1.18-1.69),最高三分位总脂肪组织者死亡风险也更高(HR 1.35;95%CI 1.08-1.69)。低放射密度与生存无关,而BMI单独不能显著关联死亡风险。
要点
- 非转移性乳腺癌中肌肉减少症发生率34%,常被低估。
- 肌肉减少症与全因死亡风险升高独立相关(HR 1.41;95%CI 1.18-1.69)。
- 最高三分位总脂肪组织者死亡风险升高(HR 1.35;95%CI 1.08-1.69)。
核心结论
- 肌肉减少症在非转移性乳腺癌中发生率高且与全因死亡风险升高独立相关。
- 高总脂肪组织也与全因死亡风险升高相关。
- CT测量的身体成分预后信息优于BMI。
研究设计与样本
- 数据来自Kaiser Permanente of Northern California和Dana Farber Cancer Institute。
- 分析诊断时临床CT测量的肌肉减少症、低肌肉放射密度和总脂肪组织与全因死亡的关系。
主要发现
- 中位年龄54岁(范围18-80),中位随访6.0年。
- 1086例(34%)存在肌肉减少症,1199例(37%)存在低肌肉放射密度。
- 肌肉减少症者较无肌肉减少症者全因死亡风险更高(HR 1.41;95%CI 1.18-1.69)。
- 最高三分位总脂肪组织者较低三分位者全因死亡风险更高(HR 1.35;95%CI 1.08-1.69)。
- 肌肉减少症合并高总脂肪组织者死亡风险最高(HR 1.89;95%CI 1.30-2.73)。
关键数值与推荐
- 低肌肉放射密度与生存无显著关联。
- BMI单独与全因死亡无显著关联,且不能恰当识别身体成分相关死亡风险。
临床怎么用
- 对非转移性乳腺癌患者可考虑利用临床CT评估肌肉减少症和脂肪组织以改善预后分层。
- CT身体成分指标有助于指导优化生存结局的干预措施。
- 不应仅依赖BMI评估身体成分相关死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown. OBJECTIVE: To evaluate associations of all 3 body composition measures, derived from clinically acquired CT at diagnosis, with overall mortality in nonmetastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This observational study included 3241 women from Kaiser Permanente of Northern California and Dana Farber Cancer Institute diagnosed from January 2000 to December 2013 with stages II or III breast cancer. We calculated hazard ratios (HRs) to evaluate the associations of all-cause mortality with sarcopenia, low muscle radiodensity, and total adipose tissue (TAT). Models were adjusted for sociodemographics, tumor characteristics, treatment, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), and other body composition measures. We also evaluated the cross-classification of categories of sarcopenia (yes/no) and tertiles of TAT, with outcomes. MAIN OUTCOMES AND MEASURES: Overall survival time and all-cause mortality. RESULTS: Median (range) age of 3241 women included in this study was 54 (18-80) years, and median follow-up was 6.0 years; 1086 patients (34%) presented with sarcopenia, and 1199 patients (37%) had low muscle radiodensity. Among patients with nonmetastatic breast cancer, those with sarcopenia showed higher overall mortality (HR, 1.41; 95% CI, 1.18-1.69) compared with those without sarcopenia. Patients in the highest tertile of TAT also showed higher overall mortality (HR, 1.35; 95% CI, 1.08-1.69) compared with those in the lowest tertile. Low radiodensity was not associated with survival. In analyses of sarcopenia and TAT, highest mortality was seen in patients with sarcopenia and high TAT (HR, 1.89; 95% CI, 1.30-2.73); BMI alone was not significantly related to overall mortality and did not appropriately identify patients at risk of death owing to their body composition. CONCLUSIONS AND RELEVANCE: Sarcopenia is underrecognized in nonmetastatic breast cancer and occurs in over one-third of newly diagnosed patients. Measures of both sarcopenia and adiposity from clinically acquired CT scans in nonmetastatic patients provide significant prognostic information that outperform BMI and will help to guide interventions to optimize survival outcomes.
引用
- Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018. PMID: 29621380. doi:10.1001/jamaoncol.2018.0137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。